Squarepoint Ops LLC Buys Shares of 59,562 Eton Pharmaceuticals, Inc. $ETON

Squarepoint Ops LLC purchased a new position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 59,562 shares of the company’s stock, valued at approximately $2,156,000.

Several other large investors also recently made changes to their positions in the stock. Toth Financial Advisory Corp acquired a new position in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $43,000. Caitong International Asset Management Co. Ltd acquired a new stake in Eton Pharmaceuticals in the 4th quarter worth approximately $50,000. Persistent Asset Partners Ltd bought a new stake in Eton Pharmaceuticals during the second quarter worth approximately $90,000. State of Wyoming bought a new stake in Eton Pharmaceuticals during the second quarter worth approximately $107,000. Finally, Quantbot Technologies LP acquired a new position in Eton Pharmaceuticals during the second quarter valued at approximately $165,000. Institutional investors own 27.86% of the company’s stock.

Insiders Place Their Bets

In other Eton Pharmaceuticals news, insider David Krempa sold 25,000 shares of the stock in a transaction on Monday, August 24th. The shares were sold at an average price of $65.07, for a total value of $1,626,750.00. Following the completion of the sale, the insider owned 37,025 shares in the company, valued at $2,409,216.75. This trade represents a 40.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jennifer Mckie Adams sold 50,000 shares of Eton Pharmaceuticals stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the completion of the transaction, the director directly owned 50,000 shares of the company’s stock, valued at approximately $1,624,000. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 125,000 shares of company stock valued at $6,204,250. 16.49% of the stock is currently owned by corporate insiders.

Eton Pharmaceuticals Trading Up 0.9%

Shares of Eton Pharmaceuticals stock opened at $57.62 on Tuesday. The company’s fifty day simple moving average is $50.31 and its 200-day simple moving average is $35.27. The company has a market cap of $1.65 billion, a price-to-earnings ratio of 151.63 and a beta of 0.90. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.41. Eton Pharmaceuticals, Inc. has a 1 year low of $14.27 and a 1 year high of $66.37.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings data on Thursday, August 13th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.19 by $0.24. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%.The company had revenue of $37.59 million during the quarter, compared to the consensus estimate of $27.11 million. As a group, sell-side analysts expect that Eton Pharmaceuticals, Inc. will post 1.13 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ETON shares. HC Wainwright boosted their price objective on shares of Eton Pharmaceuticals from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, August 14th. Zacks Research upgraded shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. Finally, Craig Hallum raised their price target on Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Eton Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $67.50.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for underserved patient populations, with an emphasis on pediatric, rare disease and other difficult-to-treat conditions. The company generally pursues products with established clinical or regulatory pathways and works to bring them to market through its own commercial operations or strategic partnerships.

Eton’s marketed portfolio includes Eprontia, an oral solution formulation of topiramate used in the treatment of certain seizure disorders; Biorphen, an injectable phenylephrine product used to treat clinically important low blood pressure; and Alkindi Sprinkle, a hydrocortisone granule product for replacement therapy in children with adrenal insufficiency.